Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial
Journal of Gynecologic Oncology · 2026 · 37 (4)
DOI: 10.3802/jgo.2026.37.e70 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Jie Lin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Uterine Cervical Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, Clinical Research Center for Precision Treatment of Gynecological Malignancies of Fujian Province.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant treatments combining anti-programmed cell death 1 (PD-1) inhibitors with chemotherapy induce higher pathologic response rates than chemotherapy alone in patients with locally advanced cervical cancer (LACC). A dual blocker that targets PD-1 and cytotoxic T lymphocyte-associated protein-4, paired with de-escalated chemotherapy, may improve treatment efficacy while reducing toxicity. This study aims to evaluate the efficacy and safety of neoadjuvant iparomlimab and tuvonralimab in conjunction with reduced courses of chemotherapy for LACC. METHODS: In this multi-center, single-arm, open-label, phase II trial, patients with histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma are eligible. A total of 43 patients diagnosed with International Federation of Gynecology and Obstetrics 2018 stage IB3, IIA2, IIB, or IIIC1r will receive iparomlimab and tuvonralimab (5 mg/kg, intravenously), nab-paclitaxel (60 mg/m², intravenously), and cisplatin (75-80 mg/m², intravenously) for the first cycle. Then, 2 additional cycles of iparomlimab and tuvonralimab (5 mg/kg, intravenously) were followed at 3-week intervals. After finishing 3 cycles of neoadjuvant treatment, patients who exhibit a complete response (CR) or partial response (PR) will proceed to radical surgery, and subsequent adjuvant therapy will be guided by the National Comprehensive Cancer Network guidelines. Conversely, patients with stable or progressive disease will transition to concurrent chemoradiotherapy. The primary endpoint is the pathological CR. Secondary endpoints include the objective response rate, event-free survival, major PR, disease-free survival rate, and safety. Additionally, the exploratory endpoint will focus on identifying predictive biomarkers associated with tumor response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT07055399.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Obstetrics and Gynecology, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- Department of Gynecology and Obstetrics, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
- Clinical Medical Research Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
ORCID-Profile: Jie Lin, Qiaoling Wu, Bin Liu, Haixin He, Xinye Guo, Linxia Li, Yu Jiang, Yuxiu Huang, Yingtao Lin, Tongmei He, Xiang Zheng, Sang Li, Lijun Chen, Cuibo Lin, Evangeline Li, Shengtao Zhou, Yang Sun
Förderung
- Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province
- Clinical Research Center for Precision Treatment of Gynecological Malignancies of Fujian Province
Zitieren
APA
Lin, J., Wu, Q., Liu, B., He, H., Guo, X., Li, L., Jiang, Y., Huang, Y., Lin, Y., He, T., Zheng, X., Li, S., Chen, L., Lin, C., Li, E., Zhou, S., & Sun, Y. (2026). Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial. Journal of Gynecologic Oncology, 37(4). https://doi.org/10.3802/jgo.2026.37.e70
Vancouver
Lin J, Wu Q, Liu B, He H, Guo X, Li L, et al. Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial. Journal of Gynecologic Oncology. 2026;37(4). doi:10.3802/jgo.2026.37.e70
BibTeX
@article{Lin2026,
author = {Lin, Jie and Wu, Qiaoling and Liu, Bin and He, Haixin and Guo, Xinye and Li, Linxia and Jiang, Yu and Huang, Yuxiu and Lin, Yingtao and He, Tongmei and Zheng, Xiang and Li, Sang and Chen, Lijun and Lin, Cuibo and Li, Evangeline and Zhou, Shengtao and Sun, Yang},
title = {Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial},
journal = {Journal of Gynecologic Oncology},
year = {2026},
volume = {37},
number = {4},
doi = {10.3802/jgo.2026.37.e70}
}
EUVIMED